[1] 胡伏莲.中国幽门螺杆菌研究现状[J].胃肠病学, 2007, 12(9):516-518. [2] Kusters JG,van Vliet AH,Kuipers EJ. Pathogenesis of Helicobacter pylori infection[J]. Clin Microbiol Rev,2006,19(3):449-490. [3] Kutlubay Z, Zara T,Engin B, et al. Helicobacter pylori infection and skin disorders[J].Hong Kong Med J,2014,20(4):317-324. [4] Moss SF, Leqon S, Davies J, et al. Cytokine gene expression in Helicobacter pylori associated antral gastritis [J].Gut,1994,35(11):1567-1570. [5] 马越,李景云,金少鸿. 美国临床实验室标准委员会推荐药敏试验操作方法和判断标准(2005年修订版)[J].中华医学杂志, 2005,85(17):1182-1184. [6] 刘文忠. “第五次全国幽门螺杆菌感染处理共识报告”解读[J].胃肠病学,2017,22(6):346-360. [7] Chuah SK, Tsay FW, Hsu PI, et al. A new look at anti- Helicobacter pylori therapy[J]. World J Gastroenterol, 2011,17(35):3971-3975. [8] De Francesco V,Giorgio F, Hassan C,et al. Worldwide H.pylori antibiotic resistance:a systematic review[J].J Gastrointestin Liver Dis, 2010, 19(4):409-414. [9] 王莉莉,杨超,董全江,等. 青岛地区幽门螺杆菌多重耐药现状和突变特征分析[J].国际检验医学杂志, 2015,36(24):3583-3585. [10] 汪望月, 陈光兰, 任玲玲, 等. 浙江省丽水地区幽门螺杆菌临床分离株耐药性分析[J].浙江临床医学, 2016,18(10):1903-1905. [11] Garcia M, Raymond J, Garnier M,et al. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France [J]. Antimicrob Agents Chemother, 2012,56(1):550-551. [12] Lee CC, Lee VW, Chan FK, et al. Levofloxacin-resistant Helicobacter pylori in Hong Kong [J]. Chemotherapy, 2008,54(1):50-53. [13] Taylor DE, Ge Z,Purych D, et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations [J]. Antimicrob Agents Chemother,1997,41(12):2621-2628. [14] Kim JM, Kim JS, Kim N,et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients[J]. Int J Antimicrob Agents, 2006, 28(1):6-13. [15] 宋艳斌,马文丽, 郑文岭. DNA测序中常见影响因素的研究[J].生物技术通报, 2005,21(1):44-46.
2019, Vol. 26 
